دراسة قصيدة ياسالكا لمخدوم محمد هاشم التتوي رحمه الله: دراسة تحليلية وأدبية

The Poem “Ya Salikayah” is a collection of verses. Hazrat Makhdoom Muhammad Hashim Thattavi has compiled it and the main thing is that he has compiled these verses by in keeping with the literature and eloquence and rules. Such a compilation is not just a matter of every ordinary person rather, this work can be done by a person who is well aware of the rules of making of poetry and verses. Hazrat Makhdoom Muhammad Hashim Thattavi was well aware of these rules but he had mastered it. The thesis writer has described the expression style and thoughts of Hazrat Makhdoom Muhammad Hashim Thattavi in his thesis and also tried to prove that Hazrat Makhdoom Muhammad Hashim Thattavi had special kind of proficiency in Arabic despite he was Non-Arab which can be seen in his these verses. These verses show the special style of Hazrat Makhdoom Muhammad Hashim Thattavi which thesis writer has proven and also proved that he has compiled this collection of verses in the best style. According to the research of thesis writer this poem is not still in the form of a book but in the form of a pen and paper format. And thesis writer has also tried to prove that the thoughts which are in these verses belong to Hazrat Makhdoom Thattavi himself. He used to shape thoughts into ideas before compiling these verses and then used to put his sincere poetry in it and compile it. It is estimated from these verses that it is affected when the audience hears and reads these verses.

Enhancing Oral Bioavailability of Famotidine and Roxithromycin Bcs-Iv Drugs by Nano-Emulsifying Drug Delivery System

Pre-dosage forms of Famotidine and Roxithromycin available in the market suggest that their treatment may not facilitate patients due to poor water solubility and permeability which ultimately leads to their low oral bioavailability. To reduce the draw backs associated with their systemic administration, Solid Lipid Nanoparticles (SLNs) loaded with Famotidine and Roxithromycin were fabricated as a mean of achieving boosted oral bioavailability. During fabrication of Solid Lipid Particles (SLNs), emulsion was employed as the most important precursor. Stearic acid was employd as the solid lipid phase and Tween® 80as surfactant. Polyethylene glycol and polyvinyl alcohol were used as co-surfactants. Different results in term of particles size and polydispersity index (PDI) were obtained by varying experimental conditions, i.e. concentration of surfactant, concentration of co-surfactant and stirring time. SLNs were fabricated via three different techniques (Solvent Injection, Solvent Emulsification Evaporation and Hot Melt Encapsulation) using nano-template engineering technology. Solvent Injection technique was employed for Fabrication of SLNs loaded with Roxithromycin and Famotidine. SLNs loaded with Roxithromycin and Famotidine demonstrated particle size 169.6±2.3 nm & 162.7±2.3 nm, PDI 0.462±0.02 & 0.352±0.03, zeta potential -32.6±1.9 mV & -34.35±2 mV, percent entrapment efficiency 84.36±1.3% &85±2.7%, percent drug loading capacity 2.709±0.43% & 2.74±0.33% respectively. Solvent Emulsification Evaporation method being used for preparation of SLNs loaded with Roxithromycin and Famotidine. SLNs loaded with Roxithromycin and Famotidine showed particle size 126.27±2.1 nm & 111.9±1.3 nm, PDI 0.435±0.01 & 0.464±0.03, zeta potential -36.72±2 mV & -33.46±2 mV, percent entrapment efficiency 83.61±2.3% & 84±2.7%, percent drug loading capacity 2.677±0.13% & 2.709±0.13% respectively. Hot Melt Encapsulation technique, which avoids the use of organic solvent was also being employed for Fabrication of SLNs loaded with Roxithromycin and Famotidine. SLNs loaded with Roxithromycin and Famotidine demonstrated particle size 179.7±2.3 nm & 174.8±2.1 nm, PDI 0.424±0.03 & 0.419, zeta potential -38.16±1.6 mV & -36.35 mV, percent entrapment efficiency 86% & 87±2.1%, percent drug loading capacity 2.77% & 2.81±0.13% respectively. During further characterization of loaded SLNs formulations, the white patches in the micrographs of Scanning Electron Spectroscopy (SEM) verified identical, spherical shaped and nano-metric size particles. SEM also showed that the particles size was in concordance to the data attained from Dynamic Light Scattering analysis. Fourier Transform Infrared Spectroscopy revealed no drugs-excipients interaction. Moreover, characterization via using Powdered X-Ray Diffractometer and Differential Scanning Calorimetry confirmed successful reduction in the crystalline nature of the loaded SLNs formulations. In-vitro drug release study was conducted and enhanced sustained release was found with maximum drug pay-load. Different mathematical kinetic models were employed to the drug release data to confirm the drug release kinetics and mechanism. During stability study, SLN dispersions stored at different conditions confirmed maximum stability at refrigerated condition, showing a consistent particles size and polydispersity. Moreover, tray drying technique as alternative to lyophilization was investigated and found that this technique can also be employed for SLNs drying purpose, especially for bulk production. Scanning Electron Microscopy (SEM) was conducted for the samples being prepared by tray drying technique in order to compare with the lyophilized samples, the white patches in the micrographs of both samples were almost similar in size and shape.To acquire proper solid dosage form, loaded SLNs nano-suspensions wereprocessed to obtain dried powder followed by conversion to granules and consequently filled in capsule shells. Comparative in-vitro study of the prepared capsules was conducted for dissimilarity (f1) and similarity (f2) factors determination. Dissimilarity factor greater than 65 (f1>65)showing a remarked difference compared to the marketed products. Comparative in-vivo study of the SLNs nano-suspension as well as prepared capsules with the marketed product has also been conducted. This study showed massive difference, in terms of increased Cmax as well as AUC0→24 compared to the marketed products. Overall, these results indicate that the developed Nanoparticulate Drug Delivery System of SLNs is smart enough showing significantly improved oral bilavailability with sustained drug release profile for Famotidine and Roxithromycin.